NodThera Employee Directory
Biotechnology ResearchMassachusetts, United States11-50 Employees
NodThera is a clinical-stage biotechnology company focused on developing a new class of potent and highly selective inhibitors of the NLRP3 inflammasome to treat diseases driven by chronic inflammation. Based in Boston, Massachusetts, with offices in Cambridge, UK and Boston, MA, the firm operates with a small-to-mid-sized team and pursues brain-penetrant, oral inhibitors aimed at addressing inflammatory drivers in cardiometabolic and neurologic diseases. The company targets researchers and pharmaceutical developers seeking disease-modifying options for chronic inflammatory conditions, led by its lead candidate ruvonoflast (formerly NT-0796). A recent development is that data from the Phase 1b cardiometabolic trial of ruvonoflast has been accepted for a late-breaking oral presentation at the 94th European Atherosclerosis Society Congress in 2026.